May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Comparison of Cd4+cd25+ (Regulatory) T Cell Levels in Patients Affected by Primary Open–Angle Glaucoma and Healthy Subjects
Author Affiliations & Notes
  • S.A. Gandolfi
    Ophthalmology, University of Parma, Parma, Italy
  • R. Aldigeri
    Ophthalmology, University of Parma, Parma, Italy
  • S. Bonomini
    Hematology Unit, Azienda Ospedaliera of Parma, Parma, Italy
  • G. Ferrari
    Ophthalmology, University of Parma, Parma, Italy
  • C. Sangermani
    Ophthalmology, University of Parma, Parma, Italy
  • M. Tardini
    Ophthalmology, University of Parma, Parma, Italy
  • Footnotes
    Commercial Relationships  S.A. Gandolfi, None; R. Aldigeri, None; S. Bonomini, None; G. Ferrari, None; C. Sangermani, None; M. Tardini, None.
  • Footnotes
    Support  University of Parma Grant FIL2004
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.A. Gandolfi, R. Aldigeri, S. Bonomini, G. Ferrari, C. Sangermani, M. Tardini; Comparison of Cd4+cd25+ (Regulatory) T Cell Levels in Patients Affected by Primary Open–Angle Glaucoma and Healthy Subjects . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : A protective autoimmunity has been proposed to minimize injury to the optic nerve by reducing the secondary degeneration of neurons. This neuroprotective autoimmune response is suppressed by a subpopulation of regulatory T cells (Tregs) represented by CD4+CD25+ T cells. These cells express a specific transcription factor, Foxp3, required for their function and development. The aim of our study is to measure the levels of regulatory T–cells (CD4+CD25+) in patients affected by primary open–angle glaucoma(POAG) and age–matched controls.

Methods: : Whole blood was obtained by 21 patients affected by POAG (mean age:73 yrs, range 54–82) and 20 age–matched controls (mean age: 72 yrs, range 61–83) with negative history for neurodegenerative, autoimmune diseases, cancer, viral infection. Flow cytometric analysis was used to determine the CD4+CD25+high lymphocyte population and in a second step in 6 cases (mean age=75 yrs) and 6 controls (mean age=68) it was similarly tested a more specific Treg marker (Foxp3).

Results: : The percentage of Tregs was calculated over the total amount of CD3+CD4+. The median value of Tregs (%) in POAG patients was 10.79 and 7.41 in controls. The U Mann Whitney showed a highly significant difference (p<0.001) between the two groups. In the second set of data the median percentage of Foxp3+Tregs was 8.03 in patients and 5.36 in controls, confirming a highly significant difference (p=0.01).

Conclusions: : Patients with POAG express a higher amount of Treg(CD4+CD25+) than age–matched controls.

Keywords: neuroprotection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×